A detailed history of New Mexico Educational Retirement Board transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, New Mexico Educational Retirement Board holds 22,100 shares of ARWR stock, worth $434,264. This represents 0.01% of its overall portfolio holdings.

Number of Shares
22,100
Previous 22,100 -0.0%
Holding current value
$434,264
Previous $574,000 25.44%
% of portfolio
0.01%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

BUY
$27.21 - $39.48 $16,326 - $23,687
600 Added 2.79%
22,100 $632,000
Q1 2024

Apr 17, 2024

SELL
$27.21 - $39.48 $16,326 - $23,687
-600 Reduced 2.71%
21,500 $989,000
Q2 2023

Jul 17, 2023

BUY
$25.16 - $41.38 $72,964 - $120,002
2,900 Added 15.1%
22,100 $788,000
Q1 2023

May 03, 2023

BUY
$23.68 - $38.51 $61,568 - $100,126
2,600 Added 15.66%
19,200 $488,000
Q2 2022

Jul 21, 2022

SELL
$27.79 - $50.61 $136,171 - $247,989
-4,900 Reduced 22.79%
16,600 $584,000
Q2 2021

Jul 13, 2021

BUY
$62.15 - $90.32 $223,740 - $325,152
3,600 Added 20.11%
21,500 $1.78 Million
Q4 2020

Feb 02, 2021

SELL
$43.82 - $85.37 $131,460 - $256,110
-3,000 Reduced 14.35%
17,900 $1.37 Million
Q3 2020

Oct 28, 2020

BUY
$33.21 - $51.27 $694,089 - $1.07 Million
20,900 New
20,900 $900,000
Q3 2020

Oct 27, 2020

SELL
$33.21 - $51.27 $790,398 - $1.22 Million
-23,800 Closed
0 $0
Q1 2020

Jun 11, 2020

BUY
$20.56 - $63.12 $133,640 - $410,280
6,500 Added 37.57%
23,800 $685,000
Q4 2019

Feb 10, 2020

BUY
$28.14 - $73.01 $486,822 - $1.26 Million
17,300 New
17,300 $1.1 Million

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track New Mexico Educational Retirement Board Portfolio

Follow New Mexico Educational Retirement Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Mexico Educational Retirement Board, based on Form 13F filings with the SEC.

News

Stay updated on New Mexico Educational Retirement Board with notifications on news.